Fig. 4
From: Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
Enhanced antitumor activities against primary tumors. C57BL/6J mice were subcutaneously inoculated with 1 × 106 MC38 cells. BALB/c mice were subcutaneously inoculated with 1 × 106 4T1 cells or 1.5 × 106 CT26 cells. When tumor sizes reached ~100 mm3 (counted as day 1), the mice were intratumorally injected with 50 μL of OAd-SIRPα-Fc (1 × 108 pfu per tumor) for the MC38 model (a), OAd-Siglec10-Fc (3 × 108 pfu per tumor) for the 4T1 model (b), and OAd-TIGIT-Fc (1 × 108 pfu per tumor) for the CT26 model (c) on days 1, 4, 7, 10, and 13. The treatment regimens for PBS, Ad or OAd-null in the corresponding models were consistent with those for the armed OAds. Tumor volume was monitored in mice bearing MC38 (d, n = 5), 4T1 (e, n = 7), or CT26 tumors (f, n = 5). Data are represented as mean ± SEM. Survival curves of mice bearing MC38 (g), 4T1 (h), and CT26 tumors (i) (n = 10). j Two days after the third injection, the treated tumors were collected and analyzed by flow cytometry to calculate the percentages of infiltrating CD8+ T cells, Tregs, TAMs and mMDSCs in MC38 tumors. n = 3 mice. Data are represented as mean ± SD. (*p < 0.05, **p < 0.01, ***p < 0.001)
